The stock of Arcutis Biotherapeutics Inc (ARQT) has gone up by 6.06% for the week, with a -4.64% drop in the past month and a 21.43% rise in the past quarter. The volatility ratio for the week is 5.34%, and the volatility levels for the past 30 days are 7.96% for ARQT. The simple moving average for the last 20 days is 9.71% for ARQT stock, with a simple moving average of 28.46% for the last 200 days.
Is It Worth Investing in Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Right Now?
The 36-month beta value for ARQT is also noteworthy at 1.86. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ARQT is 104.41M, and at present, short sellers hold a 13.77% of that float. The average trading volume of ARQT on May 06, 2025 was 2.49M shares.
ARQT) stock’s latest price update
The stock of Arcutis Biotherapeutics Inc (NASDAQ: ARQT) has increased by 1.12 when compared to last closing price of 15.24. Despite this, the company has experienced a 6.06% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-02 that WESTLAKE VILLAGE, Calif., May 02, 2025 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 26,500 restricted stock units of Arcutis’ common stock to three newly hired employees.
Analysts’ Opinion of ARQT
Many brokerage firms have already submitted their reports for ARQT stocks, with H.C. Wainwright repeating the rating for ARQT by listing it as a “Buy.” The predicted price for ARQT in the upcoming period, according to H.C. Wainwright is $19 based on the research report published on December 30, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see ARQT reach a price target of $15. The rating they have provided for ARQT stocks is “Buy” according to the report published on August 28th, 2024.
Mizuho gave a rating of “Buy” to ARQT, setting the target price at $8 in the report published on January 03rd of the previous year.
ARQT Trading at 5.06% from the 50-Day Moving Average
After a stumble in the market that brought ARQT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.18% of loss for the given period.
Volatility was left at 7.96%, however, over the last 30 days, the volatility rate increased by 5.34%, as shares surge +4.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +18.36% upper at present.
During the last 5 trading sessions, ARQT rose by +6.06%, which changed the moving average for the period of 200-days by +50.05% in comparison to the 20-day moving average, which settled at $14.05. In addition, Arcutis Biotherapeutics Inc saw 10.62% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARQT starting from Matsuda Masaru, who sale 5,030 shares at the price of $15.20 back on May 02 ’25. After this action, Matsuda Masaru now owns 204,399 shares of Arcutis Biotherapeutics Inc, valued at $76,453 using the latest closing price.
Watanabe Todd Franklin, the of Arcutis Biotherapeutics Inc, sale 11,448 shares at $15.19 during a trade that took place back on May 02 ’25, which means that Watanabe Todd Franklin is holding 913,795 shares at $173,917 based on the most recent closing price.
Stock Fundamentals for ARQT
Current profitability levels for the company are sitting at:
- -0.65 for the present operating margin
- 0.9 for the gross margin
The net margin for Arcutis Biotherapeutics Inc stands at -0.71. The total capital return value is set at -0.48. Equity return is now at value -113.76, with -40.58 for asset returns.
Based on Arcutis Biotherapeutics Inc (ARQT), the company’s capital structure generated 0.41 points at debt to capital in total, while cash flow to debt ratio is standing at -1.01. The debt to equity ratio resting at 0.7. The interest coverage ratio of the stock is -4.73.
Currently, EBITDA for the company is -109.62 million with net debt to EBITDA at -0.36. When we switch over and look at the enterprise to sales, we see a ratio of 9.55. The receivables turnover for the company is 2.69for trailing twelve months and the total asset turnover is 0.56. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.15.
Conclusion
In summary, Arcutis Biotherapeutics Inc (ARQT) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
